Characterization of APOE Christchurch carriers in 455,306 UK Biobank participants
Preprint
Abstract
Importance: A few case studies have reported the APOE Christchurch (APOECh) variant to confer protective effects for Alzheimer’s disease (AD) and a higher risk of premature cardiovascular disease (CVD). However, these studies primarily focused on a single individual or siblings from the same family. Objective: We sought to characterize the clinical characteristics of individuals with APOECh variation in 455,306 participants of the UK Biobank (UKB) to determine whether it is associated with AD protection or cardiovascular risk. Design, Setting, and Participants: A total of 37 individuals were identified as heterozygous carriers of APOECh in UKB sequencing data as of March 2022, resulting in allele frequency consistent with gnomAD (4.06×10 −5 ). We limited our study to 36 European carriers and generated a noncarrier cohort matched on age, sex, and ancestry. Case-control analyses were performed to evaluate the frequency of 11 binary traits and differences in distributions of 80 quantitative traits and 10 polygenic risk scores (PRS) for lipid traits, CVD, and neurodegenerative diseases. Main Outcomes and Measures: We compared the frequencies of binary traits (binomial distribution probability) and distributions of quantitative traits and PRS (Kolmogorov-Smirnov test). Results: All 37 carriers are free of AD and only 4 have a parental history of AD. There are 22 out of 37 carriers with > 1 cardiovascular (CV) condition in clinical and/or self-reported data, two of whom passed away due to heart disease. However, frequency of CVD, dyslipidemia, and hypertension is not enriched in carriers compared with matched non-carriers. Additionally, apolipoprotein B (apoB) is significantly lower in APOECh carriers before (p=0.004) and after statin adjustment (p=0.04). Comparisons of PRS show that carriers and non-carriers have a similar genetic burden of developing dyslipidemia and CVD, but carriers have lower PRS-based AD risk (p=0.02). Conclusions and Relevance: This study demonstrates that APOECh carriers may have lower levels of apoB and a lower risk of AD. Cohorts with enriched cases are needed to further investigate whether the protective effect is linked to APOE genotypes or other factors. Key Points: Question: How does APOE Christchurch (APOECh) variant influence risk of Alzheimer’s disease (AD), cardiovascular disease, and dyslipidemia? Findings: APOECh carriers do not have an elevated risk of dyslipidemia. However, carriers have lower levels of apolipoprotein B (apoB). Comparing polygenic risk scores of carriers vs. noncarriers of APOECh shows carriers are at a lower risk of developing AD before but not after adjusting for multiple comparisons. Meaning: Carriers of APOECh may have a lower risk of developing AD due to lower apoB; however, further epidemiological and model organism studies are needed to validate these observations from the current study.Keywords
This publication has 35 references indexed in Scilit:
- ApoE2 and Alzheimer′s disease: time to take a closer lookNeural Regeneration Research, 2016
- ApoE variant p.V236E is associated with markedly reduced risk of Alzheimer’s diseaseMolecular Neurodegeneration, 2014
- Apolipoprotein E mutations: a comparison between lipoprotein glomerulopathy and type III hyperlipoproteinemiaClinical and Experimental Nephrology, 2014
- APOE-ε2 and APOE-ε4 Correlate With Increased Amyloid Accumulation in Cerebral VasculatureJournal of Neuropathology & Experimental Neurology, 2013
- Apolipoprotein E Genotype Is Associated With CT Angiography Spot Sign in Lobar Intracerebral HemorrhageStroke, 2012
- Plasma Apolipoprotein Levels Are Associated with Cognitive Status and Decline in a Community Cohort of Older IndividualsPLOS ONE, 2012
- APOE ε2 is associated with intact cognition but increased Alzheimer pathology in the oldest oldNeurology, 2009
- Two Italian kindreds carrying the Arg136→Ser mutation of the Apo E gene: development of premature and severe atherosclerosis in the presence of epsilon 2 as second alleleNutrition, Metabolism and Cardiovascular Diseases, 2003
- Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer DiseaseJAMA, 1997
- Apolipoprotein E2-Christchurch (136 Arg----Ser). New variant of human apolipoprotein E in a patient with type III hyperlipoproteinemia.Journal of Clinical Investigation, 1987